TRIBUNPONTIANAK.CO.ID- HIV cases are still a threat to us everywhere.
Many teenagers have lost their future because they are exposed to HIV AIDS for the rest of their lives.
The United States Food and Drug Administration (FDA) has authorized the use of pre-exposure prophylaxis (PrEP) HIV injections.
This drug is called Apretude, to reduce the risk of developing HIV-1 infection in adults and adolescents. This is the first HIV preventive injectable drug.
To note, HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).
• Syarifah Liza Putri Sriyati Alkadrie Chosen as HIV/AIDS Ambassador for West Kalimantan Province 2022
What’s that Apretude?
According to the official FDA website, Apretude (cabotegravir extended-release injectable suspension) is used in at-risk adults and adolescents weighing at least 35 kilograms to reduce the risk of contracting HIV.
Apretude is initially given as an injection into the buttock muscle once every month for the first two months, followed by injections once every two months.
Patients can start treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess his body’s tolerance.
In its use, PrEp requires a high level of compliance to be effective.
• World AIDS Day, 2021 Pontianak Health Office Finds 59 HIV/AIDS Cases
–
